Table 5.
Incidence of various levels of decline in eGFR from values at 6 months postrandomization in the SPRINT participants with CKD
| eGFR Reduction from Month 6, %a | No. of Events (% per 1 yr)b | Intensive Treatment Versus Standard Treatment | ||
|---|---|---|---|---|
| Intensive Treatment, n=1330 | Standard Treatment, n=1316 | HR (95% CI) | P Value | |
| 50 | 7 (0.17) | 4 (0.10) | 1.65 (0.48 to 5.62) | 0.42 |
| 40 | 15 (0.37) | 14 (0.36) | 1.01 (0.49 to 2.10) | 0.98 |
| 30 | 44 (1.09) | 35 (0.91) | 1.19 (0.76 to 1.85) | 0.44 |
a
Each patient with eGFR decline from the 6-mo value to a level below the designated threshold (30%, 40%, or 50%) was confirmed by a second laboratory test at least 90 d later. The patients with ≥40% decline in eGFR include all patients with ≥30% decline, whereas patients with ≥50% decline included all patients with ≥40% decline and ≥30% decline.
b
Number of first occurrence of these events (eGFR decline to a level below the designated threshold confirmed at least 90 d later) during the entire follow-up period after 6 months postrandomization; percentage per person-year that experienced the event is in parentheses.